Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
01/08/202406:06Alliance NewsAlliance NewsIrish manufacturing activity returns to slight growth in July
01/08/202406:04Alliance NewsAlliance NewsTOP NEWS: Chinese manufacturing activity declines unexpectedly in July
01/08/202406:02Alliance NewsAlliance NewsTOP NEWS: Japan manufacturing sector contracts in July
01/08/202406:00UK RegulatoryING posts 2Q2024 net result of €1,780 million, underpinned by strong income in Retail and Wholesale BankingEU:INGAING Groep NV
01/08/202406:00UK RegulatoryStart of Day Message
01/08/202406:00UK RegulatoryWorldline H1 2024 resultsEU:WLNWorldline
01/08/202406:00UK RegulatorySYENSQO - Second Quarter 2024 ResultsTG:2NFSyensqo SA
01/08/202406:00UK RegulatoryValneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine CandidateLSE:0OB3Valneva Se
01/08/202406:00UK RegulatoryIBA : Publication des résultats du premier semestre 2024 et conférence webTG:IOBIon Beam Applications SA
01/08/202406:00UK RegulatoryWorldline résultats S1 2024EU:WLNWorldline
01/08/202406:00UK RegulatoryArcelorMittal S.A.: ArcelorMittal reports second quarter 2024 and half year 2024 resultsEU:MTArcelorMittal
01/08/202406:00UK RegulatoryING posts 2Q2024 net result of €1,780 million, underpinned by strong income in Retail and Wholesale BankingTG:INN1ING Groep NV
01/08/202406:00UK RegulatoryPharming Group reports second quarter and first half 2024 financial results and provides business updateTG:PHGNPharming Group NV
01/08/202406:00UK RegulatoryIBA : Publication des résultats du premier semestre 2024 et conférence webEU:IBABIon Beam Applications SA
01/08/202406:00UK RegulatorySYENSQO - Résultats du Second Trimestre 2024TG:2NFSyensqo SA
01/08/202406:00UK RegulatoryValneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine CandidateTG:AYJValneva SE
01/08/202406:00UK RegulatoryIBA Notice of Half Year 2024 Results and Conference CallTG:IOBIon Beam Applications SA
01/08/202406:00UK RegulatoryValneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au mondeEU:VLAValneva SE
01/08/202406:00UK RegulatoryWorldline H1 2024 resultsTG:WO6Worldline
01/08/202406:00UK RegulatoryING posts 2Q2024 net result of €1,780 million, underpinned by strong income in Retail and Wholesale BankingBIT:1INGAING Groep NV
01/08/202406:00UK RegulatorySYENSQO - Second Quarter 2024 ResultsEU:SYENSSyensqo SA
01/08/202406:00UK RegulatoryING posts 2Q2024 net result of €1,780 million, underpinned by strong income in Retail and Wholesale BankingXE:INN1ING Groep NV
01/08/202406:00UK RegulatoryING posts 2Q2024 net result of €1,780 million, underpinned by strong income in Retail and Wholesale BankingBIT:INGAING Groep NV
01/08/202406:00UK RegulatoryWorldline résultats S1 2024TG:WO6Worldline
01/08/202406:00UK RegulatoryArcelorMittal S.A.: ArcelorMittal reports second quarter 2024 and half year 2024 resultsXE:ARRDArcelorMittal
01/08/202406:00UK RegulatoryValneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au mondeTG:AYJValneva SE
01/08/202406:00UK RegulatoryFagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024TG:4A5Fagron NV
01/08/202406:00UK RegulatoryValneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au mondeLSE:0OB3Valneva Se
01/08/202406:00UK RegulatoryFagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024EU:FAGRFagron NV
01/08/202406:00UK RegulatoryValneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine CandidateEU:VLAValneva SE